TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28973220

Group type: EXPERIMENTAL
Intervention: Individualized management strategy aimed at achieving a systolic blood pressure (SBP) within 10% of the reference value
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard management strategy of treating SBP less than 80 mm Hg or lower than 40% from the reference value
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Individualized treatment group
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 298
Study: 26535969

Group type: EXPERIMENTAL
Intervention: Extended-release hydrocodone (20-300mg) every 12 hours
Number of subjects: 391
Study: 23427068

Group type: EXPERIMENTAL
Intervention: Vertebroplasty (VP)
Number of subjects: 57
Study: 20673731

Group type: EXPERIMENTAL
Intervention: Open reduction, rigid internal fixation, and functional treatment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Closed reduction and functional treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 19059362

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Number of subjects: 5
Study: 17106197

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg once a day, increased to 100 mg twice a day after 10 days if tolerated)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (without thalidomide)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thalidomide and Control
Number of subjects: 80
Study: 14739814

Group type: EXPERIMENTAL
Intervention: Paravertebral anesthesia with continuous paravertebral postoperative analgesia using levobupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous morphine analgesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paravertebral anesthesia
Number of subjects: 20
Study: 11474348

Group type: EXPERIMENTAL
Intervention: Proceed, a gelatin‐based hemostatic sealant
Number of subjects: 127

Group type: COMPARATOR
Intervention: Gelfoam‐thrombin
Number of subjects: 127
Study: 9725293

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unenhanced MR imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT imaging
Number of subjects: 0
Study: 8112185

Group type: EXPERIMENTAL
Intervention: 50 mg miglitol 3 times a day
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 100 mg miglitol 3 times a day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 3180305

Group type: EXPERIMENTAL
Intervention: Cefotetan 2g iv every 12 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Netilmicin (150mg iv every 12 hours) plus Clindamycin (600mg iv every 8 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Netilmicin plus Clindamycin
Number of subjects: 60
Study: 30353612

Group type: EXPERIMENTAL
Intervention: Toolkit 'Children-What does it involve?' and Real-Care-Baby simulator
Number of subjects: 6
Study: 28808771

Group type: COMPARATOR
Intervention: Classical treatment (antibiotics, anti-inflammatories and low-fibre diet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatment (anti-inflammatories and low-fibre diet)
Number of subjects: 0
Study: 27656713

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily for four months
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control
Number of subjects: 379
Study: 23333003

Group type: EXPERIMENTAL
Intervention: Monitored arm (Etco2 monitoring)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control arm (clinical assessment)
Number of subjects: 50
Study: 21675061

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study: 19701035

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 16400055

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet (30% protein, 40% carbohydrate, 30% fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adequate-Protein (AP) diet (10% protein, 60% carbohydrate, 30% fat)
Number of subjects: 12
Study: 14767999

Group type: EXPERIMENTAL
Intervention: Standard care and hypertonic saline (30%) infusion to maintain serum sodium levels of 145‐155 mmol/L (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal standard of care (Group 1)
Number of subjects: 30
Study: 11416710

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 51
Study: 9296466

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin sodium, Fragmin)
Number of subjects: 1506
Study: 8095362

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall treatment with haloperidol, chlorpromazine, and perphenazine
Number of subjects: 100
Study: 3100676

Group type: EXPERIMENTAL
Intervention: Inferior dental anaesthesia via the direct intraoral approach
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mandibular conduction anaesthesia via extraoral landmarks (Gow‐Gates)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mandibular conduction anaesthesia via the tuberosity approach (Akinosi)
Number of subjects: 90
Study: 31234104

Group type: EXPERIMENTAL
Intervention: Static air support surfaces
Number of subjects: 308

Group type: COMPARATOR
Intervention: Alternating air pressure support surfaces
Number of subjects: 308
Study: 29764602

Group type: EXPERIMENTAL
Intervention: Psychiatric disorders assessment through face-to-face interview using CIDI v2.1
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Health service utilization for mental problems
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Minimally adequate treatment for psychiatric disorders
Number of subjects: 250
Study: 25675385

Group type: COMPARATOR
Intervention: Saline (0.9%) infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recombinant human TNF‐α (1000 ng/m(2) · h) infusion
Number of subjects: 12
Study: 24325959

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI) measuring global systolic function (s') and global diastolic function (e')
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI) measuring both global systolic function (s') and global diastolic function (e')
Number of subjects: 391
Study: 22786601

Group type: EXPERIMENTAL
Intervention: Breakthrough Series implementation program
Number of subjects: 1657

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1657
Study: 19183162

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 108
Study: 17944658

Group type: EXPERIMENTAL
Intervention: HIV patients on ART
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16
Study: 15887898

Group type: EXPERIMENTAL
Intervention: RWU (reference warm up based on FWU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: RWU‐10 (warm up intensity diminished by 10% compared to RWU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: RWU+10 (warm up intensity increased by 10% compared to RWU)
Number of subjects: 9

Group type: COMPARATOR
Intervention: NWU (no warm up)
Number of subjects: 9
Study: 12643380

Group type: EXPERIMENTAL
Intervention: Pleural tent procedure (group 1)
Number of subjects: 200
Study: 9884132

Group type: COMPARATOR
Intervention: Ethanol 0.2 g/kg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ethanol 0.4 g/kg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ethanol 0.8 g/kg
Number of subjects: 49
Study: 7614105

Group type: EXPERIMENTAL
Intervention: Industrial labourers
Number of subjects: 947

Group type: COMPARATOR
Intervention: Nomads
Number of subjects: 947
Study: 1513972

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy using portable liquid oxygen systems
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment by oxygen
Number of subjects: 0
Study: 6388253

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 30706471

Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 306

Group type: COMPARATOR
Intervention: Cu‐IUD
Number of subjects: 306
Study: 29324864

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine with artemether-lumefantrine (AL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg primaquine with artemether-lumefantrine (AL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine with dihydroartemisinin-piperaquine (DP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: AL plus 0.25 mg/kg primaquine (G6PD-normal)
Number of subjects: 90

Group type: COMPARATOR
Intervention: AL plus 0.40 mg/kg primaquine (G6PD-normal)
Number of subjects: 90
Study: 27126076

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Exposure Therapy (ET)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 73
Study: 24186565

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 22417813

Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Generic Information (GI)
Number of subjects: 539
Study: 21109086

Group type: EXPERIMENTAL
Intervention: Pharyngeal packing during nasal surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: No pharyngeal packing during nasal surgery
Number of subjects: 100
Study: 18248393

Group type: EXPERIMENTAL
Intervention: Oral folic acid supplementation for 2 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15781541

Group type: EXPERIMENTAL
Intervention: 100 microg clonidine
Number of subjects: 41

Group type: COMPARATOR
Intervention: 2 mL saline (placebo)
Number of subjects: 41
Study: 12559267

Group type: EXPERIMENTAL
Intervention: 11 mL of 0.2% oxybuprocaine hydrochloride gel
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 11 mL of plain lubricating gel
Number of subjects: 133

Group type: COMPARATOR
Intervention: No gel injection
Number of subjects: 133
Study: 10342416

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three opioids (morphine, pethidine, fentanyl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changing opioids
Number of subjects: 0
Study: 7924357

Group type: EXPERIMENTAL
Intervention: Contextual changes (shift from above to below water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Same test of visual recognition
Number of subjects: 0
Study: 2681675

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (CHx) used twice daily for 6 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (CHx)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 142845

Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: streptozotocin
Number of subjects: 125

Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 125
Study: 30257588

Group type: EXPERIMENTAL
Intervention: 0.125 mg methylergometrine per os twice a day for 10 days
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 31419272

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28368311

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 40
Study: 26409403

Group type: EXPERIMENTAL
Intervention: Real repetitive sacral root magnetic stimulation (rSMS; 15 Hz with a total of 1500 pulses/session) for 10 sessions
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham repetitive sacral root magnetic stimulation
Number of subjects: 44
Study: 23993053

Group type: EXPERIMENTAL
Intervention: Two 4.5‐mm screws
Number of subjects: 10

Group type: COMPARATOR
Intervention: Three 3.5‐mm screws
Number of subjects: 10
Study: 21194921

Group type: EXPERIMENTAL
Intervention: Acupressure bands (Pressure Right) (Group A)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Sham placebo bands (Group P)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Acupressure bands (Group A)
Number of subjects: 340
Study: 18312754

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg/day for 1 month
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard clopidogrel 75 mg/day
Number of subjects: 17
Study: 17003431

Group type: EXPERIMENTAL
Intervention: Educational cartoon story, reward stickers, and an information sheet for the parents
Number of subjects: 310

Group type: COMPARATOR
Intervention: Picture to color (reference group)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 310
Study: 12675873

Group type: EXPERIMENTAL
Intervention: Risk factors (urinary protein ≥3 g/day and systolic blood pressure ≥140 mm Hg)
Number of subjects: 0
Study: 11140330

Group type: EXPERIMENTAL
Intervention: Low-dose interferon alpha (IFN-alpha) treatment
Number of subjects: 11
Study: 8812622

Group type: EXPERIMENTAL
Intervention: Fentanyl anesthesia (FA)
Number of subjects: 17
Study: 8243376

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) as add-on treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) as add-on therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 0
Study: 2869850

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of catecholamines with alpha 2 agonist activity (60-120 min)
Number of subjects: 0
Study: 30231101

Group type: EXPERIMENTAL
Intervention: Conical interface (CI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Flat-to-flat interface (FI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Platform-switch interface (PS)
Number of subjects: 141
Study: 27741949

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 50 mg every 6 hours
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 197
Study: 25335327

Group type: EXPERIMENTAL
Intervention: Qigui Mixture (QM), 200 mL per day, twice daily, and Qigui Huoxue Lotion (QHL) foot bath for 10-15 min every evening for 3 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mecobalamine Tablet, 500 microg each time, 3 times per day
Number of subjects: 62
Study: 21851147

Group type: EXPERIMENTAL
Intervention: Process simulations (mental simulations of seeing the dentist)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control condition (mental simulations of the outcome of seeing the dentist)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Process simulations
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 75
Study: 19854523

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (comprehensive disease management alone)
Number of subjects: 19
Study: 17874333

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16252735

Group type: EXPERIMENTAL
Intervention: Matrine injection (150 mg once a day for two weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (other same hepatinica)
Number of subjects: 122
Study: 12356155

Group type: EXPERIMENTAL
Intervention: Combined electrocautery pencil and suction with intravenous infusion catheter
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional method with electrocautery pencil and separate metal suction tube
Number of subjects: 80
Study: 10358229

Group type: EXPERIMENTAL
Intervention: Alcoholic solution
Number of subjects: 47

Group type: COMPARATOR
Intervention: Regular handwashing (liquid soap and water)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 47
Study: 8954418

Group type: EXPERIMENTAL
Intervention: Streptokinase/streptodornase (Varidase) in a hydrogel (KY Jelly)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hydrogel alone
Number of subjects: 17
Study: 2014088

Group type: EXPERIMENTAL
Intervention: 0.5% podofilox
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7049308

Group type: EXPERIMENTAL
Intervention: Preoperative intraparietal (intra-incisional) injection of cefoxitin
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no cefoxitin)
Number of subjects: 181
Study: 31734556

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 30203774

Group type: EXPERIMENTAL
Intervention: Sorafenib combined with transcatheter arterial chemoembolization (TACE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 0
Study: 26783095

Group type: EXPERIMENTAL
Intervention: Ranibizumab monthly
Number of subjects: 1185
Study: 24194506

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide plus metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin (3 months) followed by metformin (9 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin (24 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23055415

Group type: EXPERIMENTAL
Intervention: IV delta‐9‐tetrahydrocannabinol (THC) 2.5 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19376789

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block (Group A, n=21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Group B, n=21)
Number of subjects: 42
Study: 17902186

Group type: EXPERIMENTAL
Intervention: 120 mg Ginkgo biloba extract (GBE)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 15139796

Group type: EXPERIMENTAL
Intervention: Oral administration of 6.9 mg [14C]ciclesonide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.64 mg [14C]ciclesonide
Number of subjects: 6
Study: 11167279

Group type: EXPERIMENTAL
Intervention: Ocular blood flow tonometer (OBF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Tonopen XL
Number of subjects: 99

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 99
Study: 9747866

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, and 5-flurouracil) dose-intensive treatment
Number of subjects: 992
Study: 7873475

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study: 3279143

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 31006955

Group type: EXPERIMENTAL
Intervention: Lidocaine-Propitocain Cream (EMLA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29622355

Group type: EXPERIMENTAL
Intervention: Stent graft placement after balloon angioplasty
Number of subjects: 98

Group type: COMPARATOR
Intervention: Balloon angioplasty alone
Number of subjects: 98
Study: 27151903

Group type: EXPERIMENTAL
Intervention: 17α‐hydroxyprogesterone caproate treatment
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Cervical length
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve
Number of subjects: 657
Study: 25614597

Group type: EXPERIMENTAL
Intervention: Breath holding (BH) in preeclamptic women
Number of subjects: 50

Group type: COMPARATOR
Intervention: Breath holding (BH) in normotensive women
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Breath holding (BH) in both groups
Number of subjects: 50
Study: 24024320

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Chinese kidney-nourishing medicine (Tiankui capsule)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Electroacupuncture alone
Number of subjects: 67
Study: 20699507

Group type: EXPERIMENTAL
Intervention: ALT testing in seronegative blood donors
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ALT testing
Number of subjects: 200
Study: 18629471

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 14
Study: 16616164

Group type: EXPERIMENTAL
Intervention: manualized 24-session treatment incorporating motivational interviewing and emotion coping and communication skills
Number of subjects: 16
Study: 12865901

Group type: EXPERIMENTAL
Intervention: Pentagastrin (cholecystokinin-B receptor agonist)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10859510

Group type: EXPERIMENTAL
Intervention: interferon-alpha/isotretinoin
Number of subjects: 15

Group type: COMPARATOR
Intervention: interferon-alpha/placebo
Number of subjects: 15